Interest in immunotherapy for patients with mutations increased after reports of upregulation of PD-L1 expression in mutant EGFR and ALK cells, and improved survival in mutant EGFR-driven murine lung cancer models with PD-1 axis blockade [19,20,21]. This evidence concerns the gene EGFR and lung carcinoma.